title: Management of heart failure: crossing boundary over to the surgical country.
abstract: Pharmacologic therapy of heart failure appears to have reached its zenith. Few new agents are likely to replace conventional therapy. It is time for a paradigm shift in heart failure management. Aggressive surgical strategies to remodel the failing ventricle will shape heart failure therapy in the decade ahead. The articles that follow will describe in detail the advances that have been made in "crossing the boundary" to surgical treatment of advanced heart failure.
authors.affiliation: Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114, USA. gdec@partners.org
authors.forename: G William
authors.initials: GW
authors.lastname: Dec
mesh_terms: D018421:Cardiomyoplasty / Q000379:methods; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006333:Heart Failure / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D016027:Heart Transplantation; D006353:Heart-Assist Devices; D006801:Humans; D008297:Male; D018579:Patient Selection; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016019:Survival Analysis; D013903:Thoracic Surgery / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents